Randomized study combining interferon and glatiramer acetate in multiple sclerosis

Keyphrases

• Interferon-α (IFN-α) 100%
• Multiple Sclerosis 100%
• Glatiramer Acetate 100%
• Magnetic Resonance Imaging 66%
• Risk Reduction 33%
• Image Quality Metrics 33%
• Combination Therapy 33%
• Disease-free 33%
• Multiple Sclerosis Functional Composite 33%
• Relapse Risk 33%
• Disability 16%
• Randomized Controlled Study 16%
• Imaging Results 16%
• New Lesion 16%
• Clinical Differences 16%
• Clinical Benefit 16%
• Composite Score 16%
• Relapsing-remitting multiple Sclerosis 16%
• Expanded Disability Status Scale 16%
• Lesion Volume 16%
• Annualized Relapse Rate 16%
• Comparative Efficacy 16%
• Intramuscularly 16%
• Lesion Activity 16%
• Results Combination 16%

Neuroscience

• Interferon 100%
• Multiple Sclerosis 100%
• Glatiramer Acetate 100%
• Magnetic Resonance Imaging 66%
• Expanded Disability Status Scale 16%
• Relapsing Remitting Multiple Sclerosis 16%
• Artificial Neural Network 16%